MarketPulse

MST-0312

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Mestag's MST-0312 Advances to AACR Stage Ahead of Mid-2026 Clinical Launch

Mestag Therapeutics' FAP-targeted bispecific antibody MST-0312 selected for late-breaking AACR presentation in April 2026, with Phase 1 trials expected to begin mid-year.
JNJMRKsolid tumorsbispecific antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Mestag Therapeutics

Mestag Therapeutics Secures $40M to Advance FAP-Targeted Cancer Immunotherapy

Mestag Therapeutics closes $40M financing and appoints leadership to advance FAP-targeted cancer immunotherapy MST-0312 into Phase 1 clinical trials.
JNJclinical trialbispecific antibody